mocetinostat: Clinical Trials

22 trials of mocetinostat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 8 terminated, 2 active not recruiting, 1 withdrawn. 15 Phase 2, 13 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 215Completed 8, Terminated 7
Phase 113Completed 7, Terminated 3, Active not recruiting 2, Withdrawn 1

Follow mocetinostat: new trials by email Literature Review of mocetinostat trials Research Report on mocetinostat

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma
Vinorelbine, Mocetinostat - Rhabdomyosarcoma
Phase 1Active not recruitingJonsson Comprehensive Cancer Center142020-05-142026-07-17
Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
Mocetinostat, Durvalumab - Squamous Cell Carcinoma, Head And Neck, Squamous Cell Carcinoma Mouth
Phase 1WithdrawnUniversity Health Network, Toronto2017-10-102017-12-29
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
Pembrolizumab, Guadecitabine, Mocetinostat - Lung Cancer
Phase 1Active not recruitingMemorial Sloan Kettering Cancer Center282017-08-042026-08-05
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Glesatinib, Sitravatinib, Mocetinostat - Carcinoma, Non-Small-Cell Lung
Phase 2TerminatedMirati Therapeutics Inc.1612016-11-072024-04-22
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Mocetinostat - 50 mg, Mocetinostat - 70 mg, Mocetinostat - 90 mg - Advanced Cancer
Phase 1 / Phase 2TerminatedMirati Therapeutics Inc.832016-06-012021-04-06
SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma
Mocetinostat, Gemcitabine - Metastatic Leiomyosarcoma
Phase 2CompletedSarcoma Alliance for Research through Collaboration202015-11-122019-01-29
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Mocetinostat Plus Brentuximab Vedotin - Hodgkin Lymphoma
Phase 1 / Phase 2CompletedMemorial Sloan Kettering Cancer Center72015-04-222022-05-12
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Mocetinostat - Lymphoma, Relapsed and Refractory
Phase 1 / Phase 2TerminatedMemorial Sloan Kettering Cancer Center72014-10-012024-03-08
Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes
Mocetinostat - Urothelial Carcinoma
Phase 2CompletedMirati Therapeutics Inc.172014-10-012017-09-01
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
Mocetinostat, Azacitidine - Myelodysplastic Syndrome
Phase 1 / Phase 2CompletedMirati Therapeutics Inc.182013-12-012017-09-14
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Azacitidine, MGCD0103 - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Phase 2TerminatedMirati Therapeutics Inc.62008-06-012015-05-08
MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
MGCD0103 and Azacitidine - Hodgkin Lymphoma, Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)
Phase 2TerminatedMirati Therapeutics Inc.232007-10-012015-07-01
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
MGCD0103 & Docetaxel - Breast Cancer, Lung Cancer
Phase 1TerminatedMirati Therapeutics Inc.542007-08-012015-01-08
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
MGCD0103 - Lymphocytic Leukemia, Chronic
Phase 2CompletedMirati Therapeutics Inc.212007-01-012015-07-01
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
MGCD0103, Gemcitabine - Tumors
Phase 1 / Phase 2CompletedMirati Therapeutics Inc.472006-09-012015-07-01
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
MGCD0103 - Myelogenous Leukemia, Acute, Myelodysplastic Syndromes
Phase 2TerminatedMirati Therapeutics Inc.352006-09-012015-07-01
Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
MGCD0103 - Hodgkin's Lymphoma
Phase 2TerminatedMirati Therapeutics Inc.512006-08-012015-07-03
Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
MGCD0103 - Lymphoma
Phase 2CompletedMirati Therapeutics Inc.742006-08-012015-07-01
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
MGCD0103 - Myelodysplastic Syndrome, Acute Myelogenous Leukemia
Phase 1 / Phase 2CompletedMirati Therapeutics Inc.662006-01-012015-07-01
A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes
MGCD0103 - Leukemia, Myelodysplastic Syndromes
Phase 1CompletedMirati Therapeutics Inc.292005-02-012015-01-08

Showing 20 of 22. Sign in to see all of them.

Conditions studied

Myelodysplastic Syndromes (6)  ·  Recurrence (4)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Hodgkin Disease (3)  ·  Leukemia (3)  ·  Leukemia, Myeloid, Acute (3)  ·  Lung Neoplasms (2)  ·  Lymphoma (2)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Neoplasm Metastasis (2)  ·  Neoplasms (2)  ·  Breast Neoplasms (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Carcinoma, Transitional Cell (1)

Sponsors

Mirati Therapeutics Inc. (16)  ·  Memorial Sloan Kettering Cancer Center (3)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Sarcoma Alliance for Research through Collaboration (1)  ·  University Health Network, Toronto (1)

Countries

United States (21)  ·  Canada (10)  ·  United Kingdom (1)

Top investigators

Gregory Reid, MSc, MBA (12)  ·  Alison Moskowitz, MD (1)  ·  Andrew Zelenetz, MD, PhD (1)  ·  Edwin Choy, MD, PhD (1)  ·  Isan Chen, MD (1)  ·  Kathryn Arbour, MD (1)  ·  Lillian Siu, MD (1)  ·  Noah C. Federman, MD (1)  ·  Shreyas Patel, MD (1)

Results publications

PMID 22033282, PMID 30570744, PMID 39198847